Muss Hb
- Public Health, Environmental and Occupational Health
- Hematology top 10%
- Oncology
- Molecular Biology
- Immunology
- Topics
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers)Ovarian cancer diagnosis and treatment (4 papers)Endometrial and Cervical Cancer Treatments (3 papers)
- Partner nations
- United StatesCanada
In The Last Decade
Muss Hb
18 papers receiving 412 citations
Peers
Comparison fields: 5 of 70
- Public Health, Environmental and Occupational Health 123
- Hematology 116
- Oncology 105
- Molecular Biology 102
- Immunology 76
Countries citing papers authored by Muss Hb
This map shows the geographic impact of Muss Hb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muss Hb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muss Hb more than expected).
Fields of papers citing papers by Muss Hb
This network shows the impact of papers produced by Muss Hb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muss Hb. The network helps show where Muss Hb may publish in the future.
Co-authorship network of co-authors of Muss Hb
This figure shows the co-authorship network connecting the top 25 collaborators of Muss Hb. A scholar is included among the top collaborators of Muss Hb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muss Hb. Muss Hb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 11 | |
| 3 | 1 | |
| 4 | Breast Cancer in the Elderly: Treatment of Metastatic Disease. | 1 |
| 5 | Age and Gynecologic Cancer: The Gynecologic Oncology Group Experience. | 1 |
| 6 | Current status of endocrine therapy for metastatic breast cancer. | 17 |
| 7 | Chemotherapy of breast cancer in the older patient. | 13 |
| 8 | Chemotherapy of metastatic endometrial cancer. | 38 |
| 9 | Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. | 12 |
| 10 | Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. | 159 |
| 11 | 24 | |
| 12 | Vinblastine and 6-thioguanine in the treatment of advanced breast cancer. | 2 |
| 13 | 1 | |
| 14 | 41 | |
| 15 | Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix. | 7 |
| 16 | 9 | |
| 17 | 107 | |
| 18 | Adriamycin and CCNU in the treatment of advanced breast cancer. | 7 |
About Muss Hb
Muss Hb is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology, having authored 18 papers that have together received 454 indexed citations. Recurring topics across this work include Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Endometrial and Cervical Cancer Treatments (3 papers). The work is most often cited by research in Hematology (116 citations), Obstetrics and Gynecology (52 citations) and Public Health, Environmental and Occupational Health (123 citations). Muss Hb has collaborated with scholars based in United States and Canada. Frequent co-authors include DA Bass, LR DeChatelet, PS Shirley, Frederick Richards, Spurr Cl, Cooper Mr, Matthew Poole, Capizzi Rl, Gretchen Kimmick and Robert H. Choplin. Their work appears in journals such as Blood, Cancer Research and American Journal of Roentgenology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.